中文版,免去大家主旨主句翻译之苦
Printed by cai wenjie on 1/5/2014 7:24:48 AM. For personal use only. Not approved for distribution. Copyright © 2014 National Comprehensive Cancer Network, Inc., All Rights Reserved.NCCN Guidelines Version 2.2014 Non-Small Cell Lung Cancer临床分期 治疗前评估 临床评估 肺上沟肿瘤NCCN Guidelines Index NSCLC Table of Contents Discussion见治疗 (NSCL-5)IIB期(T3侵袭, N0) IIIA期 (T4外侵, N0-1; T3, N1)肺功能检测（PFT） (如果先前没做) 气管镜检查 纵隔淋巴结病理评估g 脑 MRI 对于邻近脊髓或锁骨下血管的肺上沟病灶 行脊髓+胸廓入口MRI PET/CT扫描 h (如果先前没做)胸壁见治疗(NSCL-6)近端气道 或纵隔 不可手术的肿瘤 见治疗 (NSCL-6)见治疗(NSCL-6)肿瘤转移见转移灶的治疗 孤立(NSCL-13) 或 远处转移 (NSCL-15)g评估方法包括纵隔镜，纵隔切开术, h远处转移的PET/CTEBUS, EUS, and CT引导下活检. 扫描阳性表现需要病理学或其他影像学确认。如果 PET/CT 扫描纵隔、淋巴结阳性需要病理学确认.Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.Version 2.2014, 11/04/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines ® and this illustration may not be reproduced in any form without the express written permission of NCCN®.NSCL-4
中文版,免去大家主旨主句翻译之苦
Printed by cai wenjie on 1/5/2014 7:24:48 AM. For personal use only. Not approved for distribution. Copyright © 2014 National Comprehensive Cancer Network, Inc., All Rights Reserved.NCCN Guidelines Version 2.2014 Non-Small Cell Lung Cancer临床表现NCCN Guidelines Index NSCLC Table of Contents Discussion 辅助治疗 手术 i + 化疗 k 手术 i + 化疗 k 完全根治疗性放疗 j +化疗 m 随诊 (NSCL-14) 随诊 (NSCL-14) 随诊 (NSCL-14)初始治疗 术前 同步 化放疗 j,m肺上沟肿瘤 (T3侵袭, N0-1)接近 可切除 i 肺上沟肿瘤 (T4 外侵, N0-1)术前 同步化放疗j,m可切除 再次评估手术 可能性 p 不可切除不可切除 i根治性同步 化放疗 j,m,p,q随诊 (NSCL-14)i 见手术治疗原则 j 见放射治疗原则(NSCL-B). (NSCL-C). k 见新辅助和辅助治疗的化疗方案(NSCL-D). m 见与放射治疗联用的化疗方案(NSCL-E). n R0 = 无残存肿瘤, R1 = 镜下残存肿瘤, R2 = 肉眼残存肿瘤pq如果在初始同步放化疗中的化疗没有给足剂量,如果病人不适合手术，放疗应该给到根治剂量，不能间断。 应该再给2个周期 的足量化疗.Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.Version 2.2014, 11/04/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines ® and this illustration may not be reproduced in any form without the express written permission of NCCN®.NSCL-5